Home
RXRX
RXRX News

Latest Recursion Pharmaceuticals Inc. (RXRX) News on October 23, 2024

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

GlobeNewswire

a day ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

State Street Corp's Strategic Acquisition in the Biotechnology Sector

GuruFocus.com

5 days ago

State Street Corp's Strategic Acquisition in the Biotechnology Sector

Prediction: These 2 Stocks Could Soar in 2025

Motley Fool

6 days ago

Prediction: These 2 Stocks Could Soar in 2025

Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

Zacks

7 days ago

Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Motley Fool

8 days ago

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Motley Fool

8 days ago

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Motley Fool

15 days ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

Motley Fool

16 days ago

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Zacks

20 days ago

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

MT Newswires

21 days ago

Recursion Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Trial of REC-1245 in Solid Tumors, Lymphoma

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswire

21 days ago

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

Motley Fool

24 days ago

2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Zacks

a month ago

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

a month ago

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock

Insider Monkey

a month ago

Recursion Pharmaceuticals, Inc. (RXRX): A Very Important AI Stock According to BlackRock

Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers

Insider Monkey

a month ago

Recursion Pharmaceuticals, Inc. (RXRX): Among the Worst ARK Stocks According to Short Sellers

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

Zacks

2 months ago

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

MT Newswires

2 months ago

Recursion Pharmaceuticals Says REC-994 Phase 2 Trial Shows Safety and Efficacy Trends

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

GlobeNewswire

2 months ago

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

AI specialist Recursion says lead drug is safe, but efficacy less clear

BioPharma Dive

2 months ago

AI specialist Recursion says lead drug is safe, but efficacy less clear

Is Recursion Pharmaceuticals a Warren Buffett Stock?

Motley Fool

2 months ago

Is Recursion Pharmaceuticals a Warren Buffett Stock?

Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies

Insider Monkey

2 months ago

Recursion Pharmaceuticals Inc. (RXRX): Among The Best Medical AI Companies

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Motley Fool

2 months ago

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

2 months ago

Is Recursion Pharmaceuticals Stock a Buy?

These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter

Investopedia

2 months ago

These Stocks in Nvidia's Portfolio Took a Hit in the Second Quarter

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Motley Fool

2 months ago

Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks

Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move

Motley Fool

2 months ago

Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

Motley Fool

2 months ago

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

MT Newswires

2 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $343,000, According to a Recent SEC Filing

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

Benzinga

2 months ago

AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

GlobeNewswire

2 months ago

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

MT Newswires

2 months ago

Recursion Pharmaceuticals, Exscientia Shares Rise as Companies Agree to Combine

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

2 months ago

Recursion Pharmaceuticals: Q2 Earnings Snapshot

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

GlobeNewswire

2 months ago

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

GlobeNewswire

2 months ago

Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Reuters

2 months ago

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

GlobeNewswire

2 months ago

Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT

Is Recursion Pharmaceuticals a Millionaire-Maker?

Motley Fool

3 months ago

Is Recursion Pharmaceuticals a Millionaire-Maker?

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

GlobeNewswire

3 months ago

Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

3 months ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks

Motley Fool

3 months ago

99.9% of Nvidia's $380 Million Investment Portfolio Has Been Put to Work in These 4 Artificial Intelligence (AI)-Inspired Stocks

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Motley Fool

3 months ago

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

Zacks

3 months ago

Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know

3 Millionaire-Maker Artificial Intelligence (AI) Stocks

Motley Fool

3 months ago

3 Millionaire-Maker Artificial Intelligence (AI) Stocks

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

3 months ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

3 months ago

Is Recursion Pharmaceuticals Stock a Buy?

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

Motley Fool

3 months ago

1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

Motley Fool

3 months ago

These Nvidia-Backed Artificial Intelligence (AI) Stocks Could Soar 73% to 89% Higher, According to Wall Street

MT Newswires

3 months ago

KeyBanc Cuts Price Target on Recursion Pharmaceuticals to $12 From $16, Maintains Overweight Rating

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Zacks

3 months ago

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)

GuruFocus.com

4 months ago

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Premarket Thursday

MT Newswires

4 months ago

Recursion Pharmaceuticals Prices $200 Million Stock Offering

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

GlobeNewswire

4 months ago

Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock

MT Newswires

4 months ago

Recursion Pharmaceuticals Plans $200 Million Public Offering

Recursion Announces Proposed Offering of Class A Common Stock

GlobeNewswire

4 months ago

Recursion Announces Proposed Offering of Class A Common Stock

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Zacks

4 months ago

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

GlobeNewswire

4 months ago

Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day

MT Newswires

4 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $278,880, According to a Recent SEC Filing

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

PR Newswire

4 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

Business Wire

4 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts

AFP

4 months ago

New Zealand scraps plan to tax livestock burps, farts

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

The Wall Street Journal

4 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

Business Wire

4 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

UK Unemployment Rises in Sign Inflationary Pressures Cool

Bloomberg

4 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Simply Wall St.

4 months ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Here's Why New Toyo International Holdings (SGX:N08) Has Caught The Eye Of Investors

Simply Wall St.

4 months ago

Here's Why New Toyo International Holdings (SGX:N08) Has Caught The Eye Of Investors

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

4 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Motley Fool

4 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Seoul resumes loudspeaker propaganda against North

AFP

4 months ago

Seoul resumes loudspeaker propaganda against North

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

Simply Wall St.

4 months ago

Barnes Group's (NYSE:B three-year decrease in earnings delivers investors with a 29% loss

American Software Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.

4 months ago

American Software Full Year 2024 Earnings: EPS Beats Expectations

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Simply Wall St.

4 months ago

Harley-Davidson (NYSE:HOG) Hasn't Managed To Accelerate Its Returns

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

4 months ago

Best Buy First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

3 Mistakes That Can Get Your Costco Membership Canceled

Motley Fool

4 months ago

3 Mistakes That Can Get Your Costco Membership Canceled

Nvidia Owns These 4 Stocks. Here’s How They’re Doing.

Barrons.com

4 months ago

Nvidia Owns These 4 Stocks. Here’s How They’re Doing.

MT Newswires

5 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim

Motley Fool

5 months ago

Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim

Recursion to Participate in Upcoming Investor Conferences

GlobeNewswire

5 months ago

Recursion to Participate in Upcoming Investor Conferences

Cathie Wood Owns These 2 AI Stocks. Should You?

Motley Fool

5 months ago

Cathie Wood Owns These 2 AI Stocks. Should You?

Is Recursion Pharmaceuticals Stock a Millionaire-Maker?

Motley Fool

5 months ago

Is Recursion Pharmaceuticals Stock a Millionaire-Maker?

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)

GuruFocus.com

5 months ago

Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX)

Hedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock

Insider Monkey

5 months ago

Hedge Funds are Loading Up on This NVIDIA Corp (NVDA) Partner Stock

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

GlobeNewswire

5 months ago

Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

GlobeNewswire

5 months ago

Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

2 Stocks That Could 10x by 2035

Motley Fool

5 months ago

2 Stocks That Could 10x by 2035

Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock

Zacks

5 months ago

Here is What to Know Beyond Why Recursion Pharmaceuticals, Inc. (RXRX) is a Trending Stock

Director Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX)

GuruFocus.com

5 months ago

Director Blake Borgeson Sells 20,054 Shares of Recursion Pharmaceuticals Inc (RXRX)

What's the Difference Between Biotech Stocks and TechBio Stocks?

Motley Fool

5 months ago

What's the Difference Between Biotech Stocks and TechBio Stocks?

MT Newswires

5 months ago

Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

GlobeNewswire

5 months ago

Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry

Cathie Wood Is Buying This Under-the-Radar AI Stock

Motley Fool

5 months ago

Cathie Wood Is Buying This Under-the-Radar AI Stock

Recursion Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Recursion Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

GuruFocus.com

5 months ago

Recursion Pharmaceuticals Inc (RXRX) Q1 2024 Earnings: Revenue Surpasses Estimates Amid ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript

Insider Monkey

5 months ago

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2024 Earnings Call Transcript

MT Newswires

5 months ago

Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Tops Revenue Estimates

Associated Press Finance

5 months ago

Recursion Pharmaceuticals: Q1 Earnings Snapshot

Share on Social Networks: